Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products ...

Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S.

David Denton; Executive Vice President, Chief Financial Officer; Pfizer Inc Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Alexandre De Germay; Executive Vice President ...

Pfizer's CEO said tariff uncertainty is hindering ... In a first-quarter earnings call on Tuesday, chief executive Albert Bourla was asked what incentives he would want to see in tariff ...

Q1 2025 Earnings Call Transcript April 29, 2025 Pfizer Inc. beats earnings expectations. Reported EPS is $0.92, expectations ...

Pfizer CEO Albert Bourla said Tuesday that uncertainty surrounding President Donald Trump’s proposed pharmaceutical tariffs is discouraging the company from making additional investments in U.S.